Upstream Bio Inc Receivables Turnover Ratio (UPB), from the second quarter 2026 to the second quarter 2025 current and historic results, rankings and more - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Upstream Bio Inc   (NASDAQ: UPB)
 

Upstream Bio Inc Accounts Receivables Turnover Ratio from the second quarter 2026 to the second quarter 2025

Quarterly Results, Trends, Rankings, Statistics


Accounts Receivable turnover ratio remained unchanged during the second quarter 2026, compared to the previous quarter at 4 pointing to a challenging and on top of that deteriorating business climate for the Major Pharmaceutical Preparations industry. Average collection period, for Upstream Bio Inc 's accounts receivable remained unchanged at 91 days, in the Jun 30 2026 quarter.

If we take a look into Healthcare sector 494 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 2455 to 3023.

What is Receivable Turnover Ratio?
What is Upstream Bio Inc Selling?


What is Receivable Turnover Ratio?




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

UPB Receivables Turnover Ratio (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Receivable Change -17.61 % 82.69 % 8.97 % 12.52 % 856.12 %
Y / Y Revenue Change -17.5 % 82.69 % 8.97 % 12.52 % 83.73 %
Receivable Turnover Ratio (TTM) 4 4 4 4 4
UPB's Total Ranking # 3023 # 2455 # 3412 # 1751 # 3036
Accounts Receivable average collection period days 91 91 91 91 91
Seq. Receivable Change -25.34 % 54.79 % -2.2 % -27.11 % 65.55 %
Seq. Revenue Change -25.24 % 54.79 % -2.2 % -27.11 % 65.55 %


Receivable Turnover Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 163
Healthcare Sector # 495
Overall Market # 3023

Receivable Turnover Ratio Statistics
High Average Low
6.51 4.23 2.79
(Dec 31 2024)   (Jun 30 2026)





UPB Company Profile • Back to UPB Efficiency Comparisons • Compare UPB Receivables Turnover Ratio to its Competitors

Financial Statements
Upstream Bio Inc 's Accounts Receivable $ 1 Millions Visit UPB's Balance sheet
Upstream Bio Inc 's Sales TTM $ 3 Millions Visit UPB's Income Statement
Sources of UPB's Revenues Visit UPB's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
UPB's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
UPB's Growth Rates UPB's Roa UPB's Inventory Turnover Ratio UPB's Dividend Comparisons
UPB's Profitability Ratios UPB's Roi UPB's Asset Turnover Ratio UPB's Dividend Growth
UPB's Valuation Ratios UPB's Roe UPB's Financial Strength Ratios UPB's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Jun 30 2026 Receivable at quarter ending Jun 30 2026
Innoviva Inc   11.22 $ 420.630  Millions$ 37.491  Millions
Lifeloc Technologies Inc   11.19 $ 9.269  Millions$ 0.828  Millions
Veracyte Inc   11.07 $ 544.735  Millions$ 49.194  Millions
International Stem Cell Corporation  10.91 $ 9.514  Millions$ 0.872  Millions
Caredx Inc   10.81 $ 458.089  Millions$ 42.359  Millions
C4 Therapeutics Inc   10.65 $ 35.039  Millions$ 3.290  Millions
Radnet Inc   10.53 $ 2,268.932  Millions$ 215.450  Millions
Kymera Therapeutics Inc   10.50 $ 105.000  Millions$ 10.000  Millions
Irhythm Holdings Inc   10.42 $ 825.702  Millions$ 79.250  Millions
Integrated Biopharma Inc  10.38 $ 42.568  Millions$ 4.101  Millions
Viemed Healthcare Inc   10.36 $ 301.606  Millions$ 29.102  Millions
Lensar Inc   10.33 $ 60.264  Millions$ 5.836  Millions
Immucell Corporation  10.30 $ 29.777  Millions$ 2.891  Millions
Addus Homecare Corp  10.25 $ 1,475.610  Millions$ 143.923  Millions
Dariohealth Corp   10.23 $ 21.196  Millions$ 2.072  Millions
Biodesix Inc   10.21 $ 102.939  Millions$ 10.081  Millions
Kestra Medical Technologies Ltd   10.00 $ 105.939  Millions$ 10.590  Millions
United Therapeutics Corporation  9.93 $ 3,154.500  Millions$ 317.550  Millions
Utah Medical Products Inc  9.88 $ 35.679  Millions$ 3.612  Millions
Biolife Solutions Inc   9.67 $ 102.718  Millions$ 10.626  Millions
The Oncology Institute Inc   9.66 $ 587.244  Millions$ 60.780  Millions
Sharps Technology Inc   9.65 $ 1.960  Millions$ 0.203  Millions
Encompass Health Corporation  9.57 $ 6,206.100  Millions$ 648.325  Millions
Septerna Inc   9.42 $ 98.882  Millions$ 10.501  Millions
Biofrontera Inc   9.33 $ 45.956  Millions$ 4.928  Millions
Enanta Pharmaceuticals Inc  9.29 $ 65.258  Millions$ 7.027  Millions
The Pennant Group Inc   9.27 $ 1,101.710  Millions$ 118.798  Millions
Crinetics Pharmaceuticals Inc   9.25 $ 42.156  Millions$ 4.558  Millions
Neuronetics Inc   9.24 $ 154.594  Millions$ 16.732  Millions
Myomo Inc   9.24 $ 44.242  Millions$ 4.790  Millions

Date modified: 2026-10-05T11:03:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.